Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. more
Time Frame | LRMR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.92% | 0.31% | -1.26% |
1-Month Return | -31.88% | 0.6% | -4.16% |
3-Month Return | -54.62% | -9.44% | -0.46% |
6-Month Return | -69.19% | -5.15% | 3.58% |
1-Year Return | -21.67% | 0.33% | 22.47% |
3-Year Return | -64.04% | 4.53% | 25.13% |
5-Year Return | -77.34% | 35.98% | 77.7% |
10-Year Return | -99.27% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 78.00K | 155.00K | 326.00K | 272.00K | 311.00K | [{"date":"2019-12-31","value":23.93,"profit":true},{"date":"2020-12-31","value":47.55,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.44,"profit":true},{"date":"2023-12-31","value":95.4,"profit":true}] |
Gross Profit | (78.00K) | (155.00K) | (326.00K) | (272.00K) | (311.00K) | [{"date":"2019-12-31","value":-7800000,"profit":false},{"date":"2020-12-31","value":-15500000,"profit":false},{"date":"2021-12-31","value":-32600000,"profit":false},{"date":"2022-12-31","value":-27200000,"profit":false},{"date":"2023-12-31","value":-31100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 23.21M | 42.80M | 50.47M | 36.53M | 41.76M | [{"date":"2019-12-31","value":46,"profit":true},{"date":"2020-12-31","value":84.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.38,"profit":true},{"date":"2023-12-31","value":82.75,"profit":true}] |
Operating Income | (23.21M) | (42.80M) | (50.47M) | (36.53M) | (41.76M) | [{"date":"2019-12-31","value":-2321400000,"profit":false},{"date":"2020-12-31","value":-4280400000,"profit":false},{"date":"2021-12-31","value":-5046500000,"profit":false},{"date":"2022-12-31","value":-3652600000,"profit":false},{"date":"2023-12-31","value":-4175800000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (23.13M) | (42.48M) | (50.64M) | (35.35M) | (36.95M) | [{"date":"2019-12-31","value":-2313200000,"profit":false},{"date":"2020-12-31","value":-4248200000,"profit":false},{"date":"2021-12-31","value":-5063600000,"profit":false},{"date":"2022-12-31","value":-3535500000,"profit":false},{"date":"2023-12-31","value":-3694900000,"profit":false}] |
Income Taxes | (93.86K) | (155.00K) | (326.00K) | (1.17M) | - | [{"date":"2019-12-31","value":-9386000,"profit":false},{"date":"2020-12-31","value":-15500000,"profit":false},{"date":"2021-12-31","value":-32600000,"profit":false},{"date":"2022-12-31","value":-117100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (23.13M) | (42.48M) | (50.64M) | (35.35M) | (36.95M) | [{"date":"2019-12-31","value":-2313200000,"profit":false},{"date":"2020-12-31","value":-4248200000,"profit":false},{"date":"2021-12-31","value":-5063600000,"profit":false},{"date":"2022-12-31","value":-3535500000,"profit":false},{"date":"2023-12-31","value":-3694900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (23.13M) | (42.33M) | (50.31M) | (34.18M) | (36.95M) | [{"date":"2019-12-31","value":-2313200000,"profit":false},{"date":"2020-12-31","value":-4232700000,"profit":false},{"date":"2021-12-31","value":-5031000000,"profit":false},{"date":"2022-12-31","value":-3418400000,"profit":false},{"date":"2023-12-31","value":-3694900000,"profit":false}] |
EPS (Diluted) | (13.20) | (3.94) | (2.97) | (1.54) | (0.85) | [{"date":"2019-12-31","value":-1320,"profit":false},{"date":"2020-12-31","value":-394,"profit":false},{"date":"2021-12-31","value":-297,"profit":false},{"date":"2022-12-31","value":-154,"profit":false},{"date":"2023-12-31","value":-85,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LRMR | |
---|---|
Cash Ratio | 12.51 |
Current Ratio | 13.10 |
Quick Ratio | 13.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LRMR | |
---|---|
ROA (LTM) | -28.55% |
ROE (LTM) | -44.50% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LRMR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LRMR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.12 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Larimar Therapeutics Inc (LRMR) share price today is $3.29
Yes, Indians can buy shares of Larimar Therapeutics Inc (LRMR) on Vested. To buy Larimar Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LRMR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Larimar Therapeutics Inc (LRMR) via the Vested app. You can start investing in Larimar Therapeutics Inc (LRMR) with a minimum investment of $1.
You can invest in shares of Larimar Therapeutics Inc (LRMR) via Vested in three simple steps:
The 52-week high price of Larimar Therapeutics Inc (LRMR) is $13.68. The 52-week low price of Larimar Therapeutics Inc (LRMR) is $3.01.
The price-to-earnings (P/E) ratio of Larimar Therapeutics Inc (LRMR) is
The price-to-book (P/B) ratio of Larimar Therapeutics Inc (LRMR) is 1.12
The dividend yield of Larimar Therapeutics Inc (LRMR) is 0.00%
The market capitalization of Larimar Therapeutics Inc (LRMR) is $209.92M
The stock symbol (or ticker) of Larimar Therapeutics Inc is LRMR